Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2011-002667-14-CZ
EUCTR2011-002667-14-CZ
Active, not recruiting
Phase 1

Effect of vaccination in patients with recurrent respiratory papillomatosis– can we improve the quality of life of these patients?

Institute of Hematology and Blood Transfusion0 sites50 target enrollmentJune 30, 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsSilgard

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Institute of Hematology and Blood Transfusion
Enrollment
50
Status
Active, not recruiting
Last Updated
7 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 30, 2011
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Institute of Hematology and Blood Transfusion

Eligibility Criteria

Inclusion Criteria

  • •Patients with RRP which sign the informed consent form with both parts of the study will be enrolled.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 40
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 10

Exclusion Criteria

  • •Patients who experience severe side effects of vaccination after the first or second dose will not be vaccinated with the third dose and they will be excluded from the study. Patients who will not receive all three doses within one year and 30 days will be also excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Therapeutic vaccination in patients with chronic hepatitis C genotype 1 using four courses of 8 + 6 + 6 + 6 intramuscular injections of 50 µg E1y at 3 week intervals: a multicenter, 3:1 randomized, double-blind, placebo-controlled, parallel-group study over 157 weeks in 122 patients
ISRCTN71794661Innogenetics NV (Belgium)122
Recruiting
Phase 1
VEGFR1/2 Peptide Vaccine in Patients with Recurrent, Progressive and Refractory Brain TumorsRecurrent, Progressive and Refractory Brain Tumors(hemangiopericytoma, hemangioblastoma, WHO grade II or III meningioma, chordoma, ependymoma)
JPRN-UMIN000029005Keio university school of medicine20
Active, not recruiting
Not Applicable
To understand the effect of booster dose vaccine on covid inadequate/negative antibody auto immune negative patients
CTRI/2021/12/038928Dr Padmanabha Shenoy
Active, not recruiting
Phase 1
SARS-CoV-2 vaccination response in patients with haematologicaldisease
EUCTR2021-001107-33-NLMUMC743
Active, not recruiting
Phase 1
Immunological responses after concomitant vaccination with the yellow fever-vaccine and the TBE-vaccine, or JE-vaccinePrevention of TBE or Japanece encephalitis by co-vaccination with the yellow fever vaccineTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2017-002137-32-SEHans-Gustaf Ljunggren140